β-2 Adrenergic receptor gene polymorphism and response to propranolol in cirrhosis

Table 1 Demographic profile of the study population

	Arg16-Gln27 (n = 7)	Compound heterozygotes (n = 38)	Gly16-Glu/Gln27 (n = 19)	P value
Sex (M/F)	5/2	27/11	11/8	0.630
Age (yr), mean ± SD	51.60 ± 10.91	49.02 ± 22.52	51.95 ± 8.76	0.733
Etiology
Hepatitis B	5	32	14	0.425
Alcohol	1	4	2
Cryptogenic	1	1	3
Primary biliary cirrhosis	0	1	0
Alcohol intake, Y/N	0/7	6/32	3/16	0.756
History of bleeding, Y/N	2/5	8/30	5/14	0.858
Ascites, Y/N	0/7	11/27	5/14	0.332
Albumin, g/L	32.88 ± 5.85	32.36 ± 5.63	33.13 ± 4.72	0.668
Total bilirubin (μmol/L)	46.99 ± 35.92	40.76 ± 23.91	52.61 ± 69.65	0.072
Prothrombin time (s)	16.18 ± 2.23	15.84 ± 2.30	15.22 ± 2.56	0.713
Serum sodium (mmol/L)	138.50 ± 5.43	138.30 ± 4.74	139.12 ± 4.8	0.768
Child-Pugh score	6.86 ± 1.21	6.61 ± 1.52	6.74 ± 1.91	0.168
VP (mmHg)	21.35 ± 3.02	22.08 ± 3.26	21.69 ± 2.78	0.367

Table 2 Heart rate and VP changes after propranolol according to β₂-AR gene polymorphisms

Variables	Gly16-Glu/Gln27 (n = 19)		Compound heterozygotes (n = 38)		Arg16-Gln27 (n = 7)
	Baseline	7 d	Baseline	7 d	Baseline	7 d
HR (beats/min)	76.3 ± 2.7	60.5 ± 1.8b	75.6 ± 4.9	62.5 ± 3.6b	74.1 ± 4.7	62.9 ± 3.0a
VP(mmHg)	21.35 ± 3.02	16.52 ± 1.87b	22.08 ± 3.26	19.43 ± 3.12a	21.69 ± 2.78	18.79 ± 3.15b

^aP < 0.05,

^bP < 0.01 vs baseline. HR: Heart rate.